Drug Profile

SG 3 06686

Alternative Names: SG-3-00802; SG-3-06686

Latest Information Update: 07 Nov 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Second Genome
Class Antineoplastics; Immunotherapies; Peptides
Mechanism of Action CXCR3 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Solid tumours

Most Recent Events

09 Sep 2022 Pharmacodynamics data from preclinical trial in Solid tumours presented at the 47th European Society for Medical Oncology Congress (ESMO-2022)
08 Apr 2022 Second Genome announces intention to submit IND application for Solid tumours in early 2023
08 Apr 2022 Second Genome plans a clinical trial for Solid tumours in 2023

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com